Drug
Jte 162
Jte 162: highest development phase Phase 1, developed by Shionogi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| JTE-162 NCT07247266 | Phase 1 | Cryopyrin-associated Periodic Syndromes (CAPS) |
Latest
No recent events.
Follow Jte 162 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.